{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:45:54Z","timestamp":1779889554044,"version":"3.53.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100012781","name":"Merck Sharp and Dohme","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012781","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s13555-026-01708-y","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T11:41:02Z","timestamp":1773661262000},"page":"2153-2167","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Tildrakizumab for Moderate-to-Severe Plaque Psoriasis with Diabetes: Pooled Subgroup Analysis of reSURFACE\u00a01 and reSURFACE\u00a02"],"prefix":"10.1007","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct01722331","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01729754","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5241-0915","authenticated-orcid":false,"given":"Jerry","family":"Bagel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9140-9196","authenticated-orcid":false,"given":"Ranga","family":"Gogineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4705-5303","authenticated-orcid":false,"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"1708_CR1","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s12967-014-0258-2","volume":"12","author":"S Rose","year":"2014","unstructured":"Rose S, Stansky E, Dagur PK, et al. Characterization of immune cells in psoriatic adipose tissue. J Transl Med. 2014;12:258.","journal-title":"J Transl Med"},{"issue":"4","key":"1708_CR2","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","volume":"80","author":"CA Elmets","year":"2019","unstructured":"Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073\u2013113.","journal-title":"J Am Acad Dermatol"},{"key":"1708_CR3","doi-asserted-by":"publisher","first-page":"1328297","DOI":"10.3389\/fimmu.2024.1328297","volume":"15","author":"Y Wu","year":"2024","unstructured":"Wu Y, Huang M, Chen X, et al. A genome-wide cross-trait analysis identifies shared loci and causal relationships of obesity and lipidemic traits with psoriasis. Front Immunol. 2024;15:1328297.","journal-title":"Front Immunol"},{"issue":"3","key":"1708_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.23736\/S0026-4806.24.09570-3","volume":"116","author":"DA De Luca","year":"2025","unstructured":"De Luca DA, Papara C, Hawro T, Thaci D. Psoriasis and diabetes: a review of the pathophysiological and therapeutic interconnections. Minerva Med. 2025;116(3):195\u2013222.","journal-title":"Minerva Med"},{"issue":"16","key":"1708_CR5","doi-asserted-by":"publisher","first-page":"9063","DOI":"10.3390\/ijms23169063","volume":"23","author":"S Piaserico","year":"2022","unstructured":"Piaserico S, Orlando G, Messina F. Psoriasis and cardiometabolic diseases: shared genetic and molecular pathways. Int J Mol Sci. 2022;23(16):9063.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1708_CR6","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.jaad.2015.02.1095","volume":"72","author":"AW Armstrong","year":"2015","unstructured":"Armstrong AW, Guerin A, Sundaram M, et al. Psoriasis and risk of diabetes-associated microvascular and macrovascular complications. J Am Acad Dermatol. 2015;72(6):968-77.e2.","journal-title":"J Am Acad Dermatol"},{"key":"1708_CR7","unstructured":"ILUMYA\u00ae (tildrakizumab-asmn injection, solution). Full Prescribing Information. Cranbury NJ: Sun Pharmaceutical Industries, Inc.; 2024."},{"issue":"10091","key":"1708_CR8","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","volume":"390","author":"K Reich","year":"2017","unstructured":"Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE\u00a01 and reSURFACE\u00a02): results from two randomised controlled, phase\u00a03 trials. Lancet. 2017;390(10091):276\u201388.","journal-title":"Lancet"},{"issue":"2","key":"1708_CR9","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jaad.2016.10.017","volume":"76","author":"AW Armstrong","year":"2017","unstructured":"Armstrong AW, Siegel MP, Bagel J, et al. From the medical board of the national psoriasis foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2):290\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1708_CR10","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2337\/dc17-2131","volume":"41","author":"IM Carey","year":"2018","unstructured":"Carey IM, Critchley JA, DeWilde S, Harris T, Hosking FJ, Cook DG. Risk of infection in type\u00a01 and type\u00a02 diabetes compared with the general population: a matched cohort study. Diabetes Care. 2018;41(3):513\u201321.","journal-title":"Diabetes Care"},{"issue":"2","key":"1708_CR11","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2337\/dc12-0924","volume":"36","author":"G Schett","year":"2013","unstructured":"Schett G, Kleyer A, Perricone C, et al. Diabetes is an independent predictor for severe osteoarthritis: results from a longitudinal cohort study. Diabetes Care. 2013;36(2):403\u20139.","journal-title":"Diabetes Care"},{"issue":"1","key":"1708_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13098-025-01622-x","volume":"17","author":"Z Xu","year":"2025","unstructured":"Xu Z, Ma K, Zhai Y, Wang J, Li Y. Obesity mediates the association between psoriasis and diabetes incidence: a population-based study. Diabetol Metab Syndr. 2025;17(1):51.","journal-title":"Diabetol Metab Syndr"},{"issue":"2","key":"1708_CR13","doi-asserted-by":"publisher","first-page":"e13575","DOI":"10.1111\/srt.13575","volume":"30","author":"C Gao","year":"2024","unstructured":"Gao C, Li J. Exploring the comorbidity mechanisms between psoriasis and obesity based on bioinformatics. Skin Res Technol. 2024;30(2):e13575.","journal-title":"Skin Res Technol"},{"issue":"1","key":"1708_CR14","first-page":"e52099","volume":"16","author":"WA Alajroush","year":"2024","unstructured":"Alajroush WA, Alrshid AI, Alajlan AH, et al. Psoriasis and metabolic disorders: a comprehensive meta-analysis of million adults worldwide. Cureus. 2024;16(1):e52099.","journal-title":"Cureus"},{"key":"1708_CR15","doi-asserted-by":"publisher","first-page":"605691","DOI":"10.3389\/fmed.2021.605691","volume":"8","author":"V Brazzelli","year":"2021","unstructured":"Brazzelli V, Maffioli P, Bolcato V, et al. Psoriasis and diabetes, a dangerous association: evaluation of insulin resistance, lipid abnormalities, and cardiovascular risk biomarkers. Front Med (Lausanne). 2021;8:605691.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"1708_CR16","doi-asserted-by":"publisher","first-page":"366","DOI":"10.4103\/ijdvl.IJDVL_428_18","volume":"86","author":"HY Chiu","year":"2020","unstructured":"Chiu HY, Hung CJ, Muo CH, Fan KC, Sung FC. The bidirectional association between type\u00a02 diabetes and psoriasis: two retrospective cohort studies. Indian J Dermatol Venereol Leprol. 2020;86(4):366\u201374.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"7","key":"1708_CR17","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/jamadermatol.2015.6262","volume":"152","author":"AS Lonnberg","year":"2016","unstructured":"Lonnberg AS, Skov L, Skytthe A, Kyvik KO, Pedersen OB, Thomsen SF. Association of psoriasis with the risk for type\u00a02 diabetes mellitus and obesity. JAMA Dermatol. 2016;152(7):761\u20137.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"1708_CR18","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.dsx.2019.01.009","volume":"13","author":"M Mamizadeh","year":"2019","unstructured":"Mamizadeh M, Tardeh Z, Azami M. The association between psoriasis and diabetes mellitus: a systematic review and meta-analysis. Diabetes Metab Syndr. 2019;13(2):1405\u201312.","journal-title":"Diabetes Metab Syndr"},{"issue":"2","key":"1708_CR19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jaad.2017.10.050","volume":"78","author":"MT Wan","year":"2018","unstructured":"Wan MT, Shin DB, Hubbard RA, Noe MH, Mehta NN, Gelfand JM. Psoriasis and the risk of diabetes: a prospective population-based cohort study. J Am Acad Dermatol. 2018;78(2):315-22.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1708_CR20","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.jid.2019.01.029","volume":"139","author":"K Ikumi","year":"2019","unstructured":"Ikumi K, Odanaka M, Shime H, et al. Hyperglycemia is associated with psoriatic inflammation in both humans and mice. J Invest Dermatol. 2019;139(6):1329-38.e7.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"1708_CR21","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1111\/j.1365-2133.2008.08814.x","volume":"159","author":"YB Brauchli","year":"2008","unstructured":"Brauchli YB, Jick SS, Meier CR. Psoriasis and the risk of incident diabetes mellitus: a population-based study. Br J Dermatol. 2008;159(6):1331\u20137.","journal-title":"Br J Dermatol"},{"issue":"10","key":"1708_CR22","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.3390\/ijms18102211","volume":"18","author":"SC Hu","year":"2017","unstructured":"Hu SC, Lan CE. Psoriasis and cardiovascular comorbidities: focusing on severe vascular events, cardiovascular risk factors and implications for treatment. Int J Mol Sci. 2017;18(10):2211.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"1708_CR23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/1203475415602842","volume":"20","author":"YC Lai","year":"2016","unstructured":"Lai YC, Yew YW. Psoriasis as an independent risk factor for cardiovascular disease: an epidemiologic analysis using a national database. J Cutan Med Surg. 2016;20(4):327\u201333.","journal-title":"J Cutan Med Surg"},{"issue":"1","key":"1708_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40744-019-00185-4","volume":"7","author":"A Szentpetery","year":"2020","unstructured":"Szentpetery A, Haroon M, FitzGerald O. Cardiovascular comorbidities in psoriatic disease. Rheumatol Ther. 2020;7(1):5\u201317.","journal-title":"Rheumatol Ther"},{"issue":"10","key":"1708_CR25","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1111\/jdv.18167","volume":"36","author":"AP Fernandez","year":"2022","unstructured":"Fernandez AP, Dauden E, Gerdes S, et al. Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE\u00a01 and reSURFACE\u00a02. J Eur Acad Dermatol Venereol. 2022;36(10):1774\u201383.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1708_CR26","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jaad.2019.09.042","volume":"82","author":"MG Lebwohl","year":"2020","unstructured":"Lebwohl MG, Leonardi CL, Mehta NN, et al. Tildrakizumab efficacy and safety are not altered by metabolic syndrome status in patients with psoriasis: post hoc analysis of 2 phase\u00a03 randomized controlled studies (reSURFACE\u00a01 and reSURFACE\u00a02). J Am Acad Dermatol. 2020;82(2):519\u201322.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1708_CR27","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jaad.2020.09.047","volume":"84","author":"MG Lebwohl","year":"2021","unstructured":"Lebwohl MG, Leonardi CL, Mehta NN, et al. Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: long-term results from 2 phase\u00a03 randomized controlled studies (reSURFACE\u00a01 and reSURFACE\u00a02). J Am Acad Dermatol. 2021;84(2):398\u2013407.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1708_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jaad.2021.06.883","volume":"86","author":"CW Enos","year":"2022","unstructured":"Enos CW, Ramos VL, McLean RR, et al. Comorbid obesity and history of diabetes are independently associated with poorer treatment response to biologics at 6\u00a0months: a prospective analysis in Corrona Psoriasis Registry. J Am Acad Dermatol. 2022;86(1):68\u201376.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1708_CR29","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jaad.2009.09.040","volume":"63","author":"A Menter","year":"2010","unstructured":"Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010;63(3):448\u201356.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1708_CR30","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029\u201372.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1708_CR31","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s40262-019-00743-7","volume":"58","author":"P Jauslin","year":"2019","unstructured":"Jauslin P, Kulkarni P, Li H, et al. Population-pharmacokinetic modeling of tildrakizumab (MK-3222), an anti-interleukin-23-p19 monoclonal antibody, in healthy volunteers and subjects with psoriasis. Clin Pharmacokinet. 2019;58(8):1059\u201368.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"1708_CR32","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s41999-023-00903-w","volume":"15","author":"A Chinmayee","year":"2024","unstructured":"Chinmayee A, Subbarayan S, Myint PK, et al. Diabetes mellitus increases risk of adverse drug reactions and death in hospitalised older people: the SENATOR trial. Eur Geriatr Med. 2024;15(1):189\u201399.","journal-title":"Eur Geriatr Med"},{"issue":"6","key":"1708_CR33","doi-asserted-by":"publisher","first-page":"e162","DOI":"10.37765\/ajmc.2023.89374","volume":"29","author":"CL Colvin","year":"2023","unstructured":"Colvin CL, Akinyelure OP, Rajan M, et al. Diabetes, gaps in care coordination, and preventable adverse events. Am J Manag Care. 2023;29(6):e162\u20138.","journal-title":"Am J Manag Care"},{"issue":"3","key":"1708_CR34","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/ijc.34268","volume":"152","author":"A Mailliez","year":"2023","unstructured":"Mailliez A, Ternynck C, Duhamel A, et al. Diabetes is associated with high risk of severe adverse events during chemotherapy for cancer patients: a single-center study. Int J Cancer. 2023;152(3):408\u201316.","journal-title":"Int J Cancer"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01708-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01708-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01708-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:37:44Z","timestamp":1775101064000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01708-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1708"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01708-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"31 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Jerry Bagel has received research funds for the Psoriasis Treatment Center from AbbVie, Amgen, Arcutis Biotherapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Corrona LLC, Dermavant Sciences, Dermira, Glenmark Pharmaceuticals Ltd, Janssen, Kadmon Corporation, LEO Pharma, Lilly, Lycera Corp, Menlo Therapeutics, Novartis, Ortho Dermatologics, Pfizer, Regeneron Pharmaceuticals, Sun Pharma, Taro Pharmaceutical Industries Ltd, and UCB; is or has been a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene Corporation, Janssen, Lilly, Novartis, Sun Pharma, and UCB; and is or has been a speaker for AbbVie, Celgene Corporation, Eli Lilly, Janssen, and Novartis. Dr. Ranga Gogineni is an employee of Sun Pharmaceutical Industries, Inc. Dr. Asif Shaikh is an employee of Sun Pharmaceutical Industries, Inc. Dr. Mark G. Lebwohl is an employee of Mount Sinai and receives research funds from AbbVie, Arcutis Biotherapeutics, Avotres Therapeutics, Boehringer Ingelheim, Cara Therapeutics, Clexio, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen, Pfizer, Sanofi-Regeneron, and UCB; and is a consultant for Almirall, AltruBio, Apogee, Arcutis Biotherapeutics, AstraZeneca, Atomwise, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Castle Biosciences, Celltrion, CorEvitas, Dermavant Sciences, Dermsquared, Evommune, Facilitation of International Dermatology Education, Forte Biosciences, Galderma, Genentech, Incyte, LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Sanofi-Regeneron, Seanergy, Strata, Takeda, Trevi, and Verrica.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The reSURFACE\u00a01 and reSURFACE\u00a02 study protocols were reviewed and approved by local institutional review boards or ethics panels. All participants provided written informed consent. The studies were conducted in accordance with Good Clinical Practice guidelines and the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}